Functions and Targets of miR-335 in Cancer

Lingling Ye, Fen Wang, Hao Wu, Hui Yang, Yan Yang, Yajun Ma, Aili Xue, Jing Zhu, Meili Chen, Jinyan Wang, Quan an Zhang Department of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence: Quan an ZhangDepart...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Ye L [verfasserIn] Wang F [verfasserIn] Wu H [verfasserIn] Yang H [verfasserIn] Yang Y [verfasserIn] Ma Y [verfasserIn] Xue A [verfasserIn] Zhu J [verfasserIn] Chen M [verfasserIn] Wang J [verfasserIn] Zhang QA [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	mir-335 cancer prognosis tumor biology regulation

Übergeordnetes Werk:	In: OncoTargets and Therapy - Dove Medical Press, 2009, (2021), Seite 3335-3349
Übergeordnetes Werk:	year:2021 ; pages:3335-3349

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ072550643

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ072550643
003	DE-627
005	20230502100641.0
007	cr uuu---uuuuu
008	230228s2021 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ072550643
035			\|a (DE-599)DOAJ2caa239e1cd94a8e9a24b1790dc2a154
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Ye L \|e verfasserin \|4 aut
245	1	0	\|a Functions and Targets of miR-335 in Cancer
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Lingling Ye, Fen Wang, Hao Wu, Hui Yang, Yan Yang, Yajun Ma, Aili Xue, Jing Zhu, Meili Chen, Jinyan Wang, Quan an Zhang Department of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence: Quan an ZhangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, 210000, Jiangsu, People’s Republic of ChinaEmail quananzhangjn163.comAbstract: MicroRNAs (miRNAs) are small non-coding RNAs (18&sim; 25 nt in length) that act as master regulators of eukaryotic gene expression. They might play an oncogenic or tumor-suppressive role in multiple cancers. In recent decades, several studies have focused on the functions and mechanisms of miR-335 in cancer. The expression level of miR-335 in tissues and cells varies with cancer types, and miR-335 has been proposed as a potential biomarker for the prognosis of cancer. Besides, miR-335 may serve as an oncogene or tumor suppressor via regulating different targets or pathways in tumor initiation, development, and metastasis. Furthermore, miR-335 also inﬂuences tumor microenvironment and drug sensitivity. MiR-335 is regulated by various factors such as lncRNAs and microRNAs. In this review, we reveal the functions and targets of miR-335 in various cancers and its potential application as a possible biomarker in prognostic judgment and treatment of malignant tumors.Keywords: miR-335 cancer, prognosis, tumor biology, regulation
650		4	\|a mir-335 cancer
650		4	\|a prognosis
650		4	\|a tumor biology
650		4	\|a regulation
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Wang F \|e verfasserin \|4 aut
700	0		\|a Wu H \|e verfasserin \|4 aut
700	0		\|a Yang H \|e verfasserin \|4 aut
700	0		\|a Yang Y \|e verfasserin \|4 aut
700	0		\|a Ma Y \|e verfasserin \|4 aut
700	0		\|a Xue A \|e verfasserin \|4 aut
700	0		\|a Zhu J \|e verfasserin \|4 aut
700	0		\|a Chen M \|e verfasserin \|4 aut
700	0		\|a Wang J \|e verfasserin \|4 aut
700	0		\|a Zhang QA \|e verfasserin \|4 aut
773	0	8	\|i In \|t OncoTargets and Therapy \|d Dove Medical Press, 2009 \|g (2021), Seite 3335-3349 \|w (DE-627)600307654 \|w (DE-600)2495130-4 \|x 11786930 \|7 nnns
773	1	8	\|g year:2021 \|g pages:3335-3349
856	4	0	\|u https://doaj.org/article/2caa239e1cd94a8e9a24b1790dc2a154 \|z kostenfrei
856	4	0	\|u https://www.dovepress.com/functions-and-targets-of-mir-335-in-cancer-peer-reviewed-fulltext-article-OTT \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1178-6930 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|j 2021 \|h 3335-3349

Indexfelder

author_variant	y l yl w f wf w h wh y h yh y y yy m y my x a xa z j zj c m cm w j wj z q zq
matchkey_str	article:11786930:2021----::ucinadagtomr
hierarchy_sort_str	2021
callnumber-subject-code	RC
publishDate	2021
allfields	(DE-627)DOAJ072550643 (DE-599)DOAJ2caa239e1cd94a8e9a24b1790dc2a154 DE-627 ger DE-627 rakwb eng RC254-282 Ye L verfasserin aut Functions and Targets of miR-335 in Cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Lingling Ye, Fen Wang, Hao Wu, Hui Yang, Yan Yang, Yajun Ma, Aili Xue, Jing Zhu, Meili Chen, Jinyan Wang, Quan an Zhang Department of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence: Quan an ZhangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, 210000, Jiangsu, People’s Republic of ChinaEmail quananzhangjn163.comAbstract: MicroRNAs (miRNAs) are small non-coding RNAs (18&sim; 25 nt in length) that act as master regulators of eukaryotic gene expression. They might play an oncogenic or tumor-suppressive role in multiple cancers. In recent decades, several studies have focused on the functions and mechanisms of miR-335 in cancer. The expression level of miR-335 in tissues and cells varies with cancer types, and miR-335 has been proposed as a potential biomarker for the prognosis of cancer. Besides, miR-335 may serve as an oncogene or tumor suppressor via regulating different targets or pathways in tumor initiation, development, and metastasis. Furthermore, miR-335 also inﬂuences tumor microenvironment and drug sensitivity. MiR-335 is regulated by various factors such as lncRNAs and microRNAs. In this review, we reveal the functions and targets of miR-335 in various cancers and its potential application as a possible biomarker in prognostic judgment and treatment of malignant tumors.Keywords: miR-335 cancer, prognosis, tumor biology, regulation mir-335 cancer prognosis tumor biology regulation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Wang F verfasserin aut Wu H verfasserin aut Yang H verfasserin aut Yang Y verfasserin aut Ma Y verfasserin aut Xue A verfasserin aut Zhu J verfasserin aut Chen M verfasserin aut Wang J verfasserin aut Zhang QA verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2021), Seite 3335-3349 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2021 pages:3335-3349 https://doaj.org/article/2caa239e1cd94a8e9a24b1790dc2a154 kostenfrei https://www.dovepress.com/functions-and-targets-of-mir-335-in-cancer-peer-reviewed-fulltext-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2021 3335-3349
spelling	(DE-627)DOAJ072550643 (DE-599)DOAJ2caa239e1cd94a8e9a24b1790dc2a154 DE-627 ger DE-627 rakwb eng RC254-282 Ye L verfasserin aut Functions and Targets of miR-335 in Cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Lingling Ye, Fen Wang, Hao Wu, Hui Yang, Yan Yang, Yajun Ma, Aili Xue, Jing Zhu, Meili Chen, Jinyan Wang, Quan an Zhang Department of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence: Quan an ZhangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, 210000, Jiangsu, People’s Republic of ChinaEmail quananzhangjn163.comAbstract: MicroRNAs (miRNAs) are small non-coding RNAs (18&sim; 25 nt in length) that act as master regulators of eukaryotic gene expression. They might play an oncogenic or tumor-suppressive role in multiple cancers. In recent decades, several studies have focused on the functions and mechanisms of miR-335 in cancer. The expression level of miR-335 in tissues and cells varies with cancer types, and miR-335 has been proposed as a potential biomarker for the prognosis of cancer. Besides, miR-335 may serve as an oncogene or tumor suppressor via regulating different targets or pathways in tumor initiation, development, and metastasis. Furthermore, miR-335 also inﬂuences tumor microenvironment and drug sensitivity. MiR-335 is regulated by various factors such as lncRNAs and microRNAs. In this review, we reveal the functions and targets of miR-335 in various cancers and its potential application as a possible biomarker in prognostic judgment and treatment of malignant tumors.Keywords: miR-335 cancer, prognosis, tumor biology, regulation mir-335 cancer prognosis tumor biology regulation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Wang F verfasserin aut Wu H verfasserin aut Yang H verfasserin aut Yang Y verfasserin aut Ma Y verfasserin aut Xue A verfasserin aut Zhu J verfasserin aut Chen M verfasserin aut Wang J verfasserin aut Zhang QA verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2021), Seite 3335-3349 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2021 pages:3335-3349 https://doaj.org/article/2caa239e1cd94a8e9a24b1790dc2a154 kostenfrei https://www.dovepress.com/functions-and-targets-of-mir-335-in-cancer-peer-reviewed-fulltext-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2021 3335-3349
allfields_unstemmed	(DE-627)DOAJ072550643 (DE-599)DOAJ2caa239e1cd94a8e9a24b1790dc2a154 DE-627 ger DE-627 rakwb eng RC254-282 Ye L verfasserin aut Functions and Targets of miR-335 in Cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Lingling Ye, Fen Wang, Hao Wu, Hui Yang, Yan Yang, Yajun Ma, Aili Xue, Jing Zhu, Meili Chen, Jinyan Wang, Quan an Zhang Department of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence: Quan an ZhangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, 210000, Jiangsu, People’s Republic of ChinaEmail quananzhangjn163.comAbstract: MicroRNAs (miRNAs) are small non-coding RNAs (18&sim; 25 nt in length) that act as master regulators of eukaryotic gene expression. They might play an oncogenic or tumor-suppressive role in multiple cancers. In recent decades, several studies have focused on the functions and mechanisms of miR-335 in cancer. The expression level of miR-335 in tissues and cells varies with cancer types, and miR-335 has been proposed as a potential biomarker for the prognosis of cancer. Besides, miR-335 may serve as an oncogene or tumor suppressor via regulating different targets or pathways in tumor initiation, development, and metastasis. Furthermore, miR-335 also inﬂuences tumor microenvironment and drug sensitivity. MiR-335 is regulated by various factors such as lncRNAs and microRNAs. In this review, we reveal the functions and targets of miR-335 in various cancers and its potential application as a possible biomarker in prognostic judgment and treatment of malignant tumors.Keywords: miR-335 cancer, prognosis, tumor biology, regulation mir-335 cancer prognosis tumor biology regulation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Wang F verfasserin aut Wu H verfasserin aut Yang H verfasserin aut Yang Y verfasserin aut Ma Y verfasserin aut Xue A verfasserin aut Zhu J verfasserin aut Chen M verfasserin aut Wang J verfasserin aut Zhang QA verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2021), Seite 3335-3349 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2021 pages:3335-3349 https://doaj.org/article/2caa239e1cd94a8e9a24b1790dc2a154 kostenfrei https://www.dovepress.com/functions-and-targets-of-mir-335-in-cancer-peer-reviewed-fulltext-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2021 3335-3349
allfieldsGer	(DE-627)DOAJ072550643 (DE-599)DOAJ2caa239e1cd94a8e9a24b1790dc2a154 DE-627 ger DE-627 rakwb eng RC254-282 Ye L verfasserin aut Functions and Targets of miR-335 in Cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Lingling Ye, Fen Wang, Hao Wu, Hui Yang, Yan Yang, Yajun Ma, Aili Xue, Jing Zhu, Meili Chen, Jinyan Wang, Quan an Zhang Department of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence: Quan an ZhangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, 210000, Jiangsu, People’s Republic of ChinaEmail quananzhangjn163.comAbstract: MicroRNAs (miRNAs) are small non-coding RNAs (18&sim; 25 nt in length) that act as master regulators of eukaryotic gene expression. They might play an oncogenic or tumor-suppressive role in multiple cancers. In recent decades, several studies have focused on the functions and mechanisms of miR-335 in cancer. The expression level of miR-335 in tissues and cells varies with cancer types, and miR-335 has been proposed as a potential biomarker for the prognosis of cancer. Besides, miR-335 may serve as an oncogene or tumor suppressor via regulating different targets or pathways in tumor initiation, development, and metastasis. Furthermore, miR-335 also inﬂuences tumor microenvironment and drug sensitivity. MiR-335 is regulated by various factors such as lncRNAs and microRNAs. In this review, we reveal the functions and targets of miR-335 in various cancers and its potential application as a possible biomarker in prognostic judgment and treatment of malignant tumors.Keywords: miR-335 cancer, prognosis, tumor biology, regulation mir-335 cancer prognosis tumor biology regulation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Wang F verfasserin aut Wu H verfasserin aut Yang H verfasserin aut Yang Y verfasserin aut Ma Y verfasserin aut Xue A verfasserin aut Zhu J verfasserin aut Chen M verfasserin aut Wang J verfasserin aut Zhang QA verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2021), Seite 3335-3349 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2021 pages:3335-3349 https://doaj.org/article/2caa239e1cd94a8e9a24b1790dc2a154 kostenfrei https://www.dovepress.com/functions-and-targets-of-mir-335-in-cancer-peer-reviewed-fulltext-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2021 3335-3349
allfieldsSound	(DE-627)DOAJ072550643 (DE-599)DOAJ2caa239e1cd94a8e9a24b1790dc2a154 DE-627 ger DE-627 rakwb eng RC254-282 Ye L verfasserin aut Functions and Targets of miR-335 in Cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Lingling Ye, Fen Wang, Hao Wu, Hui Yang, Yan Yang, Yajun Ma, Aili Xue, Jing Zhu, Meili Chen, Jinyan Wang, Quan an Zhang Department of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence: Quan an ZhangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, 210000, Jiangsu, People’s Republic of ChinaEmail quananzhangjn163.comAbstract: MicroRNAs (miRNAs) are small non-coding RNAs (18&sim; 25 nt in length) that act as master regulators of eukaryotic gene expression. They might play an oncogenic or tumor-suppressive role in multiple cancers. In recent decades, several studies have focused on the functions and mechanisms of miR-335 in cancer. The expression level of miR-335 in tissues and cells varies with cancer types, and miR-335 has been proposed as a potential biomarker for the prognosis of cancer. Besides, miR-335 may serve as an oncogene or tumor suppressor via regulating different targets or pathways in tumor initiation, development, and metastasis. Furthermore, miR-335 also inﬂuences tumor microenvironment and drug sensitivity. MiR-335 is regulated by various factors such as lncRNAs and microRNAs. In this review, we reveal the functions and targets of miR-335 in various cancers and its potential application as a possible biomarker in prognostic judgment and treatment of malignant tumors.Keywords: miR-335 cancer, prognosis, tumor biology, regulation mir-335 cancer prognosis tumor biology regulation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Wang F verfasserin aut Wu H verfasserin aut Yang H verfasserin aut Yang Y verfasserin aut Ma Y verfasserin aut Xue A verfasserin aut Zhu J verfasserin aut Chen M verfasserin aut Wang J verfasserin aut Zhang QA verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2021), Seite 3335-3349 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2021 pages:3335-3349 https://doaj.org/article/2caa239e1cd94a8e9a24b1790dc2a154 kostenfrei https://www.dovepress.com/functions-and-targets-of-mir-335-in-cancer-peer-reviewed-fulltext-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2021 3335-3349
language	English
source	In OncoTargets and Therapy (2021), Seite 3335-3349 year:2021 pages:3335-3349
sourceStr	In OncoTargets and Therapy (2021), Seite 3335-3349 year:2021 pages:3335-3349
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	mir-335 cancer prognosis tumor biology regulation Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	OncoTargets and Therapy
authorswithroles_txt_mv	Ye L @@aut@@ Wang F @@aut@@ Wu H @@aut@@ Yang H @@aut@@ Yang Y @@aut@@ Ma Y @@aut@@ Xue A @@aut@@ Zhu J @@aut@@ Chen M @@aut@@ Wang J @@aut@@ Zhang QA @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	600307654
id	DOAJ072550643
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ072550643</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502100641.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ072550643</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ2caa239e1cd94a8e9a24b1790dc2a154</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ye L</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Functions and Targets of miR-335 in Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Lingling Ye, Fen Wang, Hao Wu, Hui Yang, Yan Yang, Yajun Ma, Aili Xue, Jing Zhu, Meili Chen, Jinyan Wang, Quan an Zhang Department of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, People&rsquo;s Republic of ChinaCorrespondence: Quan an ZhangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, 210000, Jiangsu, People&rsquo;s Republic of ChinaEmail quananzhangjn163.comAbstract: MicroRNAs (miRNAs) are small non-coding RNAs (18&sim; 25 nt in length) that act as master regulators of eukaryotic gene expression. They might play an oncogenic or tumor-suppressive role in multiple cancers. In recent decades, several studies have focused on the functions and mechanisms of miR-335 in cancer. The expression level of miR-335 in tissues and cells varies with cancer types, and miR-335 has been proposed as a potential biomarker for the prognosis of cancer. Besides, miR-335 may serve as an oncogene or tumor suppressor via regulating different targets or pathways in tumor initiation, development, and metastasis. Furthermore, miR-335 also inﬂuences tumor microenvironment and drug sensitivity. MiR-335 is regulated by various factors such as lncRNAs and microRNAs. In this review, we reveal the functions and targets of miR-335 in various cancers and its potential application as a possible biomarker in prognostic judgment and treatment of malignant tumors.Keywords: miR-335 cancer, prognosis, tumor biology, regulation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mir-335 cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prognosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">tumor biology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">regulation</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wang F</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wu H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yang H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yang Y</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ma Y</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xue A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhu J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chen M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wang J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhang QA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">OncoTargets and Therapy</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2021), Seite 3335-3349</subfield><subfield code="w">(DE-627)600307654</subfield><subfield code="w">(DE-600)2495130-4</subfield><subfield code="x">11786930</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2021</subfield><subfield code="g">pages:3335-3349</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/2caa239e1cd94a8e9a24b1790dc2a154</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/functions-and-targets-of-mir-335-in-cancer-peer-reviewed-fulltext-article-OTT</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-6930</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2021</subfield><subfield code="h">3335-3349</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Ye L
spellingShingle	Ye L misc RC254-282 misc mir-335 cancer misc prognosis misc tumor biology misc regulation misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Functions and Targets of miR-335 in Cancer
authorStr	Ye L
ppnlink_with_tag_str_mv	@@773@@(DE-627)600307654
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	11786930
topic_title	RC254-282 Functions and Targets of miR-335 in Cancer mir-335 cancer prognosis tumor biology regulation
topic	misc RC254-282 misc mir-335 cancer misc prognosis misc tumor biology misc regulation misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc mir-335 cancer misc prognosis misc tumor biology misc regulation misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc mir-335 cancer misc prognosis misc tumor biology misc regulation misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	OncoTargets and Therapy
hierarchy_parent_id	600307654
hierarchy_top_title	OncoTargets and Therapy
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)600307654 (DE-600)2495130-4
title	Functions and Targets of miR-335 in Cancer
ctrlnum	(DE-627)DOAJ072550643 (DE-599)DOAJ2caa239e1cd94a8e9a24b1790dc2a154
title_full	Functions and Targets of miR-335 in Cancer
author_sort	Ye L
journal	OncoTargets and Therapy
journalStr	OncoTargets and Therapy
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
container_start_page	3335
author_browse	Ye L Wang F Wu H Yang H Yang Y Ma Y Xue A Zhu J Chen M Wang J Zhang QA
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Ye L
author2-role	verfasserin
title_sort	functions and targets of mir-335 in cancer
callnumber	RC254-282
title_auth	Functions and Targets of miR-335 in Cancer
abstract	Lingling Ye, Fen Wang, Hao Wu, Hui Yang, Yan Yang, Yajun Ma, Aili Xue, Jing Zhu, Meili Chen, Jinyan Wang, Quan an Zhang Department of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence: Quan an ZhangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, 210000, Jiangsu, People’s Republic of ChinaEmail quananzhangjn163.comAbstract: MicroRNAs (miRNAs) are small non-coding RNAs (18&sim; 25 nt in length) that act as master regulators of eukaryotic gene expression. They might play an oncogenic or tumor-suppressive role in multiple cancers. In recent decades, several studies have focused on the functions and mechanisms of miR-335 in cancer. The expression level of miR-335 in tissues and cells varies with cancer types, and miR-335 has been proposed as a potential biomarker for the prognosis of cancer. Besides, miR-335 may serve as an oncogene or tumor suppressor via regulating different targets or pathways in tumor initiation, development, and metastasis. Furthermore, miR-335 also inﬂuences tumor microenvironment and drug sensitivity. MiR-335 is regulated by various factors such as lncRNAs and microRNAs. In this review, we reveal the functions and targets of miR-335 in various cancers and its potential application as a possible biomarker in prognostic judgment and treatment of malignant tumors.Keywords: miR-335 cancer, prognosis, tumor biology, regulation
abstractGer	Lingling Ye, Fen Wang, Hao Wu, Hui Yang, Yan Yang, Yajun Ma, Aili Xue, Jing Zhu, Meili Chen, Jinyan Wang, Quan an Zhang Department of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence: Quan an ZhangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, 210000, Jiangsu, People’s Republic of ChinaEmail quananzhangjn163.comAbstract: MicroRNAs (miRNAs) are small non-coding RNAs (18&sim; 25 nt in length) that act as master regulators of eukaryotic gene expression. They might play an oncogenic or tumor-suppressive role in multiple cancers. In recent decades, several studies have focused on the functions and mechanisms of miR-335 in cancer. The expression level of miR-335 in tissues and cells varies with cancer types, and miR-335 has been proposed as a potential biomarker for the prognosis of cancer. Besides, miR-335 may serve as an oncogene or tumor suppressor via regulating different targets or pathways in tumor initiation, development, and metastasis. Furthermore, miR-335 also inﬂuences tumor microenvironment and drug sensitivity. MiR-335 is regulated by various factors such as lncRNAs and microRNAs. In this review, we reveal the functions and targets of miR-335 in various cancers and its potential application as a possible biomarker in prognostic judgment and treatment of malignant tumors.Keywords: miR-335 cancer, prognosis, tumor biology, regulation
abstract_unstemmed	Lingling Ye, Fen Wang, Hao Wu, Hui Yang, Yan Yang, Yajun Ma, Aili Xue, Jing Zhu, Meili Chen, Jinyan Wang, Quan an Zhang Department of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence: Quan an ZhangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, 210000, Jiangsu, People’s Republic of ChinaEmail quananzhangjn163.comAbstract: MicroRNAs (miRNAs) are small non-coding RNAs (18&sim; 25 nt in length) that act as master regulators of eukaryotic gene expression. They might play an oncogenic or tumor-suppressive role in multiple cancers. In recent decades, several studies have focused on the functions and mechanisms of miR-335 in cancer. The expression level of miR-335 in tissues and cells varies with cancer types, and miR-335 has been proposed as a potential biomarker for the prognosis of cancer. Besides, miR-335 may serve as an oncogene or tumor suppressor via regulating different targets or pathways in tumor initiation, development, and metastasis. Furthermore, miR-335 also inﬂuences tumor microenvironment and drug sensitivity. MiR-335 is regulated by various factors such as lncRNAs and microRNAs. In this review, we reveal the functions and targets of miR-335 in various cancers and its potential application as a possible biomarker in prognostic judgment and treatment of malignant tumors.Keywords: miR-335 cancer, prognosis, tumor biology, regulation
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Functions and Targets of miR-335 in Cancer
url	https://doaj.org/article/2caa239e1cd94a8e9a24b1790dc2a154 https://www.dovepress.com/functions-and-targets-of-mir-335-in-cancer-peer-reviewed-fulltext-article-OTT https://doaj.org/toc/1178-6930
remote_bool	true
author2	Wang F Wu H Yang H Yang Y Ma Y Xue A Zhu J Chen M Wang J Zhang QA
author2Str	Wang F Wu H Yang H Yang Y Ma Y Xue A Zhu J Chen M Wang J Zhang QA
ppnlink	600307654
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC254-282
up_date	2024-07-04T01:30:03.589Z
_version_	1803610073168084992
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ072550643</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502100641.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ072550643</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ2caa239e1cd94a8e9a24b1790dc2a154</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ye L</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Functions and Targets of miR-335 in Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Lingling Ye, Fen Wang, Hao Wu, Hui Yang, Yan Yang, Yajun Ma, Aili Xue, Jing Zhu, Meili Chen, Jinyan Wang, Quan an Zhang Department of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, People&rsquo;s Republic of ChinaCorrespondence: Quan an ZhangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, 210000, Jiangsu, People&rsquo;s Republic of ChinaEmail quananzhangjn163.comAbstract: MicroRNAs (miRNAs) are small non-coding RNAs (18&sim; 25 nt in length) that act as master regulators of eukaryotic gene expression. They might play an oncogenic or tumor-suppressive role in multiple cancers. In recent decades, several studies have focused on the functions and mechanisms of miR-335 in cancer. The expression level of miR-335 in tissues and cells varies with cancer types, and miR-335 has been proposed as a potential biomarker for the prognosis of cancer. Besides, miR-335 may serve as an oncogene or tumor suppressor via regulating different targets or pathways in tumor initiation, development, and metastasis. Furthermore, miR-335 also inﬂuences tumor microenvironment and drug sensitivity. MiR-335 is regulated by various factors such as lncRNAs and microRNAs. In this review, we reveal the functions and targets of miR-335 in various cancers and its potential application as a possible biomarker in prognostic judgment and treatment of malignant tumors.Keywords: miR-335 cancer, prognosis, tumor biology, regulation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mir-335 cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prognosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">tumor biology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">regulation</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wang F</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wu H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yang H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yang Y</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ma Y</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xue A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhu J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chen M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wang J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhang QA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">OncoTargets and Therapy</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2021), Seite 3335-3349</subfield><subfield code="w">(DE-627)600307654</subfield><subfield code="w">(DE-600)2495130-4</subfield><subfield code="x">11786930</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2021</subfield><subfield code="g">pages:3335-3349</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/2caa239e1cd94a8e9a24b1790dc2a154</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/functions-and-targets-of-mir-335-in-cancer-peer-reviewed-fulltext-article-OTT</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-6930</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2021</subfield><subfield code="h">3335-3349</subfield></datafield></record></collection>
score	7.399295

Nicht das Richtige dabei?

Schreiben Sie uns!

Functions and Targets of miR-335 in Cancer

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?